Dosing Completed

All volunteers have now received three doses of 2AP01 (AAVLP-HPV), our very broad spectrum HPV vaccine formulated without adjuvant. The vaccine is well tolerated and no serious adverse events (SAEs) have been observed to date. The first-in-human, phase 1, randomised, placebo-controlled, double-blind study is designed to assess the safety and tolerability and to explore the […]